We are live on ! Find out more
ASND icon

Ascendis Pharma A/S
ASND

185 hedge funds and large institutions have $7.61B invested in Ascendis Pharma A/S in 2023 Q4 according to their latest regulatory filings, with 47 funds opening new positions, 53 increasing their positions, 65 reducing their positions, and 21 closing their positions.

New
Increased
Maintained
Reduced
Closed

124% more first-time investments, than exits

New positions opened: 47 | Existing positions closed: 21

45% more funds holding in top 10

Funds holding in top 10: 11 → 16 (+5)

35% more capital invested

Capital invested by funds: $5.64B → $7.61B (+$1.96B)

30% more call options, than puts

Call options by funds: $26.8M | Put options by funds: $20.7M

16% more funds holding

Funds holding: 160 → 185 (+25)

0.18% more ownership

Funds ownership: 105.48% → 105.66% (+0.18%)

18% less repeat investments, than reductions

Existing positions increased: 53 | Existing positions reduced: 65

Holders
185
Holders Change
+25
Holders Change %
+15.63%
% of All Funds
2.7%
Holding in Top 10
16
Holding in Top 10 Change
+5
Holding in Top 10 Change %
+45.45%
% of All Funds
0.23%
New
47
Increased
53
Reduced
65
Closed
21
Calls
$26.8M
Puts
$20.7M
Net Calls
+$6.17M
Net Calls Change
+$11.8M

Top Buyers

1
PBA
Paradigm Biocapital Advisors
New York
+$35.1M
2
Massachusetts Financial Services
Massachusetts Financial Services
Massachusetts
+$25.4M
3
Invesco
Invesco
Georgia
+$23.5M
4
Westfield Capital Management
Westfield Capital Management
Massachusetts
+$22.8M
5
Citadel Advisors
Citadel Advisors
Florida
+$17.1M

Top Sellers

1
RCM
RA Capital Management
Massachusetts
-$61M
2
EAM
Eventide Asset Management
Massachusetts
-$39.3M
3
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$38.1M
4
Artisan Partners
Artisan Partners
Wisconsin
-$24.5M
5
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$19.2M
Name Holding Trade Value Shares
Change 		Change in
Stake
Millennium Management
76
Millennium Management
New York
$2.82M -$2.04M -20,461 -48%
GTC
77
Ghost Tree Capital
New York
$2.52M -$6.48M -65,000 -76%
AAA
78
Affinity Asset Advisors
New York
$2.52M -$2.63M -26,400 -57%
VOYA Investment Management
79
VOYA Investment Management
Georgia
$2.47M +$1.21M +12,165 +164%
Citigroup
80
Citigroup
New York
$2.4M -$1.35M -13,553 -42%
CSS
81
Cubist Systematic Strategies
Connecticut
$2.38M +$1.88M +18,891 New
EAM
82
Erste Asset Management
Austria
$2.36M – – –
SEC
83
Seven Eight Capital
New York
$2.35M +$1.86M +18,636 New
Barclays
84
Barclays
United Kingdom
$2.18M -$15.7K -157 -0.9%
RA
85
Rosalind Advisors
Ontario, Canada
$2.12M +$1.67M +16,800 New
ETCM
86
Evolutionary Tree Capital Management
Virginia
$2.11M +$6.88K +69 +0.4%
PNC Financial Services Group
87
PNC Financial Services Group
Pennsylvania
$2.06M +$15.9K +159 +1%
WP
88
Woodline Partners
California
$2.03M +$1.61M +16,149 New
PL
89
Parkwood LLC
Ohio
$2.03M -$200K -2,001 -11%
Acadian Asset Management
90
Acadian Asset Management
Massachusetts
$2.02M +$1.6M +16,046 New
YIH
91
Y-Intercept (HK)
Hong Kong
$1.78M +$1.41M +14,102 New
Mirae Asset Global Investments
92
Mirae Asset Global Investments
South Korea
$1.76M +$18.5K +186 +1%
JF
93
Jump Financial
Illinois
$1.68M +$1.33M +13,346 New
Nomura Asset Management
94
Nomura Asset Management
Japan
$1.6M – – –
Stifel Financial
95
Stifel Financial
Missouri
$1.58M -$1.2K -12 -0.1%
HT
96
HAP Trading
New York
$1.55M +$1.23M +12,299 New
HCA
97
Harbor Capital Advisors
Illinois
$1.52M -$204K -2,050 -15%
Handelsbanken Fonder
98
Handelsbanken Fonder
Sweden
$1.43M – – –
Wells Fargo
99
Wells Fargo
California
$1.32M +$52.8K +530 +5%
TI
100
Trexquant Investment
Connecticut
$1.24M +$984K +9,868 New
2 3
4
5 6

ASND Hedge Fund Activity: Q4 2023 in Review

185 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Ascendis Pharma A/S (ASND) for Q4 2023, worth a combined $7.61B — up 35% from $5.64B a quarter earlier.

Buyers outnumbered sellers: 47 funds opened new ASND positions and 21 closed out — a net gain of 26 holders — while 53 added to existing stakes and 65 trimmed.

The largest buyer was Paradigm Biocapital Advisors, opening a new position worth an estimated $35.1M. The largest seller was RA Capital Management, cutting an estimated $61M.

  • 185 institutional investors held Ascendis Pharma A/S (ASND) as of Q4 2023, up from 160 in Q3 2023.
  • Funds reported $7.61B of Ascendis Pharma A/S stock for Q4 2023, up 35% quarter-over-quarter.
  • 47 funds opened new Ascendis Pharma A/S positions in Q4 2023 and 21 closed out, a net change of +26 holders.
  • The largest Ascendis Pharma A/S buyer in Q4 2023 was Paradigm Biocapital Advisors, an estimated $35.1M added.
  • The largest Ascendis Pharma A/S seller in Q4 2023 was RA Capital Management, an estimated $61M sold.

Based on aggregated 13F filings for Q4 2023.